Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PowerShares Dynamic Pharmaceuticals Portfolio (PJP)

62.65
Delayed Data
As of 8:00pm ET
 +0.37 / +0.59%
Today’s Change
53.56
Today|||52-Week Range
67.35
+11.82%
Year-to-Date

Investment Objective

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research- development- manufacture- sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.

Pharma ETFs Down Post Q3 Earnings
Nov 09 / Zacks.com - Paid Partner Content
 

Performance

1 month-5.58% 3 years+0.58%
3 months+3.65% 5 years+15.37%
1 year+8.25% Since inception+13.75%
Data through 11/22/2017

Quote Details

Previous close$62.28
Open day’s range62.33 – 62.77
Net asset value (NAV)62.32 (11/21/2017)
Daily volume21,447
Average volume (3 months)48,823
Data as of 8:00pm ET, 11/22/2017

Peer Comparisonvs. Health ETFs

 PJPCategory
Performance 5-yr return+15.37%+16.79%
Expense Gross exp ratio0.56%1.33%
Risk 5 year sharpe ratio0.931.11
Net assets$662.2M$3.1B
Average market cap$17.3B$27.3B
Average P/E20.822.4
Dividend / Share--0.28%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
FHLC Fidelity® MSCI Health Care Index ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 97.52%
Consumer goods 2.48%
Business service 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie6.13%
BMY Bristol-Myers Squibb5.19%
PFE Pfizer5.17%
JNJ Johnson & Johnson5.14%
AMGN Amgen5.05%
GILD Gilead Sciences4.96%
MRK Merck4.30%
CELG Celgene3.80%
CORT Corcept Therapeutics Inc3.65%
ENTA Enanta Pharmaceuticals Inc3.38%